Aurinia Pharmaceuticals Inc. Debt Securities, Available-for-sale, Unrealized Loss
Aurinia Pharmaceuticals Inc. (AUPH) reported Debt Securities, Available-for-sale, Unrealized Loss of $292.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-06-30 was $129.00K, a 65.38% increase year-over-year.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2026-03-31 was $163.00K, a 640.91% increase year-over-year.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-12-31 was $0.00.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2025-09-30 was -$100.00K.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $1.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2026-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $292.00K 10-Q · filed 2026-08-06 | $292.00K derived: sum of 3 quarters · filed 2026-08-06 | $192.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $163.00K 10-Q · filed 2026-05-07 | $163.00K derived: sum of 2 quarters · filed 2026-08-06 | $63.00K derived: sum of 3 quarters · filed 2026-08-06 | $141.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | -$100.00K derived: sum of 2 quarters · filed 2026-08-06 | -$22.00K derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$22.00K derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $100.00K 10-Q · filed 2025-07-31 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | |
| 2025-03-31 | $22.00K 10-Q · filed 2025-05-12 | $22.00K derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $1.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |